Biogen Idec Announces Webcast of Hemophilia R&D Roundtable

Tuesday, September 21, 2010 11:54 am EDT

Dateline:

WESTON, Mass.

Public Company Information:

NASDAQ:
BIIB
US09062X1037

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB) announced today that its Hemophilia R&D Roundtable will be webcast live on Tuesday, September 28, 2010 at 1:00 p.m. EDT. To access the live webcast, please visit Biogen Idec’s Investor Relations section (investor.biogenidec.com). An archived version of the webcast will be available for 14 days following the presentation.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients worldwide benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

Contact:

Biogen Idec
Karen Jewell, 781-464-2066
Investor Relations